Absolute Risk of Oropharyngeal Cancer After an HPV16-E6 Serology Test and Potential Implications for Screening: Results From the Human Papillomavirus Cancer Cohort Consortium

Hilary A. Robbins(Centre international de recherche sur le cancer), Aida Ferreiro-Iglesias(Centre international de recherche sur le cancer), Tim Waterboer(German Cancer Research Center), Nicole Brenner(German Cancer Research Center), Mari Nygård(Cancer Registry of Norway), Noemi Bender(German Cancer Research Center), Lea Schroeder(German Cancer Research Center), Allan Hildesheim(National Cancer Institute), Michael Pawlita(German Cancer Research Center), Gypsyamber DʼSouza(Johns Hopkins University), Kala Visvanathan(Johns Hopkins University), Hilde Langseth(Cancer Registry of Norway), Nicolas F. Schlecht(Roswell Park Comprehensive Cancer Center), Lesley F. Tinker(Fred Hutch Cancer Center), Ilir Agalliu(Albert Einstein College of Medicine), Sylvia Wassertheil‐Smoller(Albert Einstein College of Medicine), Eivind Ness‐Jensen(Karolinska University Hospital), Kristian Hveem(Norwegian University of Science and Technology), Sara Grioni(Fondazione IRCCS Istituto Nazionale dei Tumori), Rudolf Kaaks(German Cancer Research Center), María‐José Sánchez(Universidad de Granada), Elisabete Weiderpass(Centre international de recherche sur le cancer), Graham G. Giles(The University of Melbourne), Roger L. Milne(The University of Melbourne), Qiuyin Cai(Vanderbilt University), William J. Blot(Vanderbilt University), Wei Zheng(Vanderbilt University), Stephanie J. Weinstein(National Cancer Institute), Demetrius Albanes(National Cancer Institute), Wen‐Yi Huang(National Cancer Institute), Neal D. Freedman(National Cancer Institute), Aimée R. Kreimer(National Cancer Institute), Mattias Johansson(Centre international de recherche sur le cancer), Paul Brennan(Centre international de recherche sur le cancer)
Journal of Clinical Oncology
June 14, 2022
Cited by 47Open Access
Full Text

Abstract

PURPOSE: Seropositivity for the HPV16-E6 oncoprotein is a promising marker for early detection of oropharyngeal cancer (OPC), but the absolute risk of OPC after a positive or negative test is unknown. METHODS: We constructed an OPC risk prediction model that integrates (1) relative odds of OPC for HPV16-E6 serostatus and cigarette smoking from the human papillomavirus (HPV) Cancer Cohort Consortium (HPVC3), (2) US population risk factor data from the National Health Interview Survey, and (3) US sex-specific population rates of OPC and mortality. RESULTS: The nine HPVC3 cohorts included 365 participants with OPC with up to 10 years between blood draw and diagnosis and 5,794 controls. The estimated 10-year OPC risk for HPV16-E6 seropositive males at age 50 years was 17.4% (95% CI, 12.4 to 28.6) and at age 60 years was 27.1% (95% CI, 19.2 to 45.4). Corresponding 5-year risk estimates were 7.3% and 14.4%, respectively. For HPV16-E6 seropositive females, 10-year risk estimates were 3.6% (95% CI, 2.5 to 5.9) at age 50 years and 5.5% (95% CI, 3.8 to 9.2) at age 60 years and 5-year risk estimates were 1.5% and 2.7%, respectively. Over 30 years, after a seropositive result at age 50 years, an estimated 49.9% of males and 13.3% of females would develop OPC. By contrast, 10-year risks among HPV16-E6 seronegative people were very low, ranging from 0.01% to 0.25% depending on age, sex, and smoking status. CONCLUSION: We estimate that a substantial proportion of HPV16-E6 seropositive individuals will develop OPC, with 10-year risks of 17%-27% for males and 4%-6% for females age 50-60 years in the United States. This high level of risk may warrant periodic, minimally invasive surveillance after a positive HPV16-E6 serology test, particularly for males in high-incidence regions. However, an appropriate clinical protocol for surveillance remains to be established.


Related Papers